Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novonesis (Novozymes) BNVZMF 90 3-Year EBITDA Growth Rate is 0.40% as of Jun. 2026, which is 95% below its 10-year median of 7.30. GuruFocus rates NVZMF with a GF Score™ of 90/100 and a GF Value™ of $64.31 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,414 Chemicals companies, Novonesis (Novozymes) B ranks worse than 50.57% on this metric.
During the past 12 months, Novonesis (Novozymes) B's average EBITDA Per Share Growth Rate was -8.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 0.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 2.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 3.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Novonesis (Novozymes) B was 21.80% per year. The lowest was -4.40% per year. And the median was 7.30% per year.
Novonesis (Novozymes) B (OTCPK:NVZMF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Novonesis (Novozymes) B 3-Year EBITDA Growth Rate Related Terms
NVZMF vs LIN, SHW, ECL: 3-Year EBITDA Growth Rate Comparison
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B 3-Year EBITDA Growth Rate vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's 3-Year EBITDA Growth Rate falls into.
Novonesis (Novozymes) B 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.40% mean?
Novonesis (Novozymes) B (NVZMF) has a 3-Year EBITDA Growth Rate of 0.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Novonesis (Novozymes) B and its competitors. This is 95% below median its historical median of 7.30. According to the industry distribution chart, Novonesis (Novozymes) B ranks #715 out of 1414 companies in the Chemicals industry, placing it in the top 50.6%.
Is Novonesis (Novozymes) B's 3-Year EBITDA Growth Rate too high?
Novonesis (Novozymes) B's current 3-Year EBITDA Growth Rate of 0.40% is 95% below median its 10-year median of 7.30. The Chemicals industry median 3-Year EBITDA Growth Rate is 0.70. Novonesis (Novozymes) B's value of 0.40% is 42.9% below this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #715 out of 1414 companies in the Chemicals industry, which is below the industry midpoint. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's 3-Year EBITDA Growth Rate compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #715 out of 1414 companies for 3-Year EBITDA Growth Rate. This places Novonesis (Novozymes) B in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 0.70. Novonesis (Novozymes) B's value of 0.40% is 42.9% below this benchmark. While the company's 10-year median is 7.30 vs. the industry median of 0.70, Novonesis (Novozymes) B has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Chemicals company?
The median 3-Year EBITDA Growth Rate among Chemicals companies is 0.70, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current 3-Year EBITDA Growth Rate of 0.40% is 42.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median 3-Year EBITDA Growth Rate is 0.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current 3-Year EBITDA Growth Rate is 0.40%, which is 95% below median its own 10-year median of 7.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMF) is currently considered Fairly Valued. The stock's GF Value™ is $64.31, compared to a current price of $65.84 — trading 2.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.40%, which is 95% below median its 10-year median of 7.30 and 42.9% below the Chemicals industry median of 0.70. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMF), the current 3-Year EBITDA Growth Rate is 0.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued.
The current stock price of $65.84 is trading 2.4% above its estimated GF Value™ of $64.31.
GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.
Key valuation signals for NVZMF:
3-Year EBITDA Growth Rate: 0.40% (95% below median its 10-year median of 7.30)
GF Value™: $64.31 vs. price of $65.84 (2.4% above fair value)
Industry Position: 42.9% below the Chemicals median (#715 of 1414)
No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
90GF Score
Get the complete analysis for NVZMF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVZMF has been successfully added to your 
